Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Breast Cancer

Clinical Trial at: Texas Oncology - Paris

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Paris

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Paris

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Paris

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Paris

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Texas Oncology - Paris

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Paris

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • Details

ClinicalTrials.gov ID: NCT03833154
Diagnosis Type: NSCLC
USOR Number: 19044

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Sherman

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Texas Oncology - Sherman

Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Details

ClinicalTrials.gov ID: NCT03955913
Diagnosis Type: NA
USOR Number: 19032

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Sherman

Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Details

ClinicalTrials.gov ID: NCT03955913
Diagnosis Type: NA
USOR Number: 19032

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Sherman

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Colon Cancer

Clinical Trial at: Texas Oncology - Sherman

An Open-label, Single-arm, Phase II Study of Regorafenib and Nivolumab in Patients With Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC)(20975)

  • Details

ClinicalTrials.gov ID: NCT04126733
Diagnosis Type: NA
USOR Number: 19096

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Rectal Cancer

Clinical Trial at: Texas Oncology - Sherman

An Open-label, Single-arm, Phase II Study of Regorafenib and Nivolumab in Patients With Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC)(20975)

  • Details

ClinicalTrials.gov ID: NCT04126733
Diagnosis Type: NA
USOR Number: 19096

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Texas Oncology - Sherman

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Pages